No headlines found.
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
Globe Newswire (Thu, 8-Jan 8:30 AM ET)
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
Globe Newswire (Thu, 13-Nov 7:30 AM ET)
Globe Newswire (Fri, 7-Nov 9:05 AM ET)
Globe Newswire (Fri, 7-Nov 9:01 AM ET)
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
Xilio Therapeutics trades on the NASDAQ stock market under the symbol XLO.
As of February 3, 2026, XLO stock price declined to $0.55 with 453,489 million shares trading.
XLO has a beta of 1.36, meaning it tends to be more sensitive to market movements. XLO has a correlation of 0.07 to the broad based SPY ETF.
XLO has a market cap of $37.39 million. This is considered a Sub-Micro Cap stock.
Last quarter Xilio Therapeutics reported $19 million in Revenue and -$.11 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.08.
In the last 3 years, XLO traded as high as $3.98 and as low as $.49.
The top ETF exchange traded funds that XLO belongs to (by Net Assets): VTI, VXF.
XLO has underperformed the market in the last year with a price return of -20.0% while the SPY ETF gained +16.6%. XLO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -34.9% and -11.6%, respectively, while the SPY returned +1.2% and +1.8%, respectively.
XLO support price is $.57 and resistance is $.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XLO shares will trade within this expected range on the day.